Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/28/2853925/0/en/4DMT-Announces-Update-on-Regulatory-Interactions-and-Development-Path-for-4D-710-for-Treatment-of-Cystic-Fibrosis.html
https://www.globenewswire.com//news-release/2024/03/04/2839515/0/en/4DMT-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/29/2838382/0/en/4DMT-Reports-Full-Year-2023-Financial-Results-and-Operational-Highlights.html
https://www.globenewswire.com//news-release/2024/02/12/2827496/0/en/4DMT-Presents-Interim-Data-from-4D-310-INGLAXA-Phase-1-2-Clinical-Trials-for-Fabry-Disease-Cardiomyopathy-at-WORLDSymposium-2024.html
https://www.globenewswire.com//news-release/2024/02/07/2824844/0/en/4D-Molecular-Therapeutics-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/02/05/2823855/0/en/4D-Molecular-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html
https://www.globenewswire.com/news-release/2024/01/29/2818842/0/en/4DMT-to-Host-Corporate-Webcast-to-Discuss-Interim-Data-from-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-in-Wet-AMD-Patients-with-Severe-Disease-Activity-High-Treatment-Burd.html
https://www.globenewswire.com//news-release/2024/01/23/2814044/0/en/4DMT-Receives-Rare-Pediatric-Disease-Designation-from-FDA-for-Aerosolized-4D-710-for-Treatment-of-Cystic-Fibrosis-Lung-Disease.html
https://www.globenewswire.com//news-release/2024/01/04/2803939/0/en/4DMT-Highlights-Recent-Clinical-Pipeline-Progress-Near-Term-Milestones-and-Organizational-Updates.html